Drug intelligence / Profile preview

68Ga-Triveoctin

Development stage: Unknown
Lead developer: TRIMT
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
Administration: Intravenous

Overview

68Ga-Triveoctin is a gallium-68-labeled cyclic RGD octapeptide trimer developed by TRIMT GmbH as a PET imaging radiopharmaceutical. It specifically targets αvβ8-integrin, a key activator of transforming growth factor β (TGF-β). αvβ8-integrin is implicated in various pathogenic processes, including tumor growth, invasion, metastasis, and epithelial-mesenchymal transition (EMT). The tracer consists of a trimeric conjugate of the cyclic peptide cyclo(GLRGDLp(NMe)K) assembled on a TRAP (triazacyclononane-triphosphinate) chelator scaffold using click chemistry. It is currently in Phase 1 clinical development for imaging cancer progression and other conditions associated with TGF-β dysregulation.

Other names: Gallium-68 TriveoctinGallium68 TriveoctinGallium 68 Triveoctin68Ga-labeled cyclic RGD octapeptide trimer68Ga-TRIMT-αvβ8-Integrin-PET tracer

Targets

αVβ3 (Integrin αVβ3)αVβ8 (Integrin alpha V beta 8)αVβ6 (Integrin αVβ6)ITGA5:ITGB1 (Integrin α5β1)

Beyond the preview

Go deeper on 68Ga-Triveoctin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 68Ga-Triveoctin.

Explore the full profile